NCT07442006RecruitingPhase 4
Glycemic Variability of Combination Therapies in T2DM
A Multicenter Study to Evaluate Efficacy and Safety
Source: ClinicalTrials.gov · Last updated 2 Mar 2026
Brief summary (registry, in English)
Glycemic Variability of Combination Therapies in T2DM
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 178 (estimated)
- First submitted
- 21 Jan 2026
- Start date
- 29 Oct 2025
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- JW Pharmaceutical
- Diseases
- Type 2 diabetes
- NCT number
- NCT07442006
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 178
- From 29 Oct 2025 to the primary completion date, 31 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of acute or chronic metabolic acidosis
- Severe hepatic impairment
- History of heart failure (NYHA Class III/IV)
Lab values
- Moderate to severe renal impairment (eGFR \< 45 mL/min/1.73m²)
Who the study is looking for
- Inadequate glycemic control despite treatment with Metformin (≥ 1,000mg/day) and SGLT-2 inhibitor.
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.